259 related articles for article (PubMed ID: 31220376)
1. Pathomechanism of dupilumab-associated inflammatory eye symptoms.
Wohlrab J; Werfel T; Wollenberg A
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e435-e436. PubMed ID: 31220376
[No Abstract] [Full Text] [Related]
2. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis.
Voorberg AN; den Dunnen WFA; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e64-e66. PubMed ID: 31465590
[No Abstract] [Full Text] [Related]
3. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
4. [Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Liberman P; Shifera AS; Berkenstock M
Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab-Induced Follicular Conjunctivitis.
Shen E; Xie K; Jwo K; Smith J; Mosaed S
Ocul Immunol Inflamm; 2019; 27(8):1339-1341. PubMed ID: 30335586
[No Abstract] [Full Text] [Related]
7. Cyclosporine 0.1% (Ikervis
Roca-Ginés J; Rahhal-Ortuño M; Torres-Navarro I; Rodríguez-Serna M; Navarro-Mira MÁ
Arch Soc Esp Oftalmol (Engl Ed); 2019 Aug; 94(8):396-399. PubMed ID: 31178231
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.
Ludriksone L; Elsner P; Malessa C; Settmacher U; Schliemann S
J Dtsch Dermatol Ges; 2020 Jul; 18(7):740-742. PubMed ID: 32212242
[No Abstract] [Full Text] [Related]
9. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use.
Jo CE; Georgakopoulos JR; Drucker AM; Piguet V; Yeung J
J Cutan Med Surg; 2020; 24(5):527-528. PubMed ID: 32449620
[No Abstract] [Full Text] [Related]
11. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration.
Wang Y; Jorizzo JL
J Am Acad Dermatol; 2021 Apr; 84(4):1010-1014. PubMed ID: 33725800
[TBL] [Abstract][Full Text] [Related]
13. Management of dupilumab-associated conjunctivitis in atopic dermatitis.
Aszodi N; Thurau S; Seegräber M; de Bruin-Weller M; Wollenberg A
J Dtsch Dermatol Ges; 2019 May; 17(5):488-491. PubMed ID: 30873757
[TBL] [Abstract][Full Text] [Related]
14. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience.
Simonetti O; Radi G; Diotallevi F; Molinelli E; Rizzetto G; Offidani A
Clin Exp Dermatol; 2021 Jul; 46(5):939-940. PubMed ID: 33576497
[No Abstract] [Full Text] [Related]
15. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
Agnihotri G; Shi K; Lio PA
Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
[TBL] [Abstract][Full Text] [Related]
16. Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
Loret L; Ninclaus V; Dendooven A; Lapeere H; Kreps EO
Eur J Dermatol; 2021 Dec; 31(6):843-844. PubMed ID: 34933837
[No Abstract] [Full Text] [Related]
17. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
18. Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?
Mastorino L; Ortoncelli M; Avallone G; Quaglino P; Ribero S
Int J Dermatol; 2022 Oct; 61(10):e370-e372. PubMed ID: 34865213
[No Abstract] [Full Text] [Related]
19. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
Bakker DS; Ariens LFM; van Luijk C; van der Schaft J; Thijs JL; Schuttelaar MLA; van Wijk F; Knol EF; Balak DMW; van Dijk MR; de Bruin-Weller MS
Br J Dermatol; 2019 May; 180(5):1248-1249. PubMed ID: 30597515
[No Abstract] [Full Text] [Related]
20. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis.
Kido-Nakahara M; Onozuka D; Izuhara K; Saeki H; Nunomura S; Takenaka M; Matsumoto M; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Saito R; Okano T; Miyagaki T; Aoki N; Nakajima K; Ichiyama S; Tonomura K; Nakagawa Y; Tamagawa-Mineoka R; Masuda K; Takeichi T; Akiyama M; Ishiuji Y; Katsuta M; Kinoshita Y; Tateishi C; Yamamoto A; Morita A; Matsuda-Hirose H; Hatano Y; Kawasaki H; Fukushima-Nomura A; Ohtsuki M; Kamiya K; Kabata Y; Abe R; Mitsui H; Kawamura T; Tsuji G; Furue M; Katoh N; Nakahara T
Allergol Int; 2024 Apr; 73(2):332-334. PubMed ID: 38151410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
